Press Releases June 3, 2026 04:05 PM

Mannatech Announces Results of Annual Shareholders’ Meeting

Mannatech shareholders approve key corporate governance proposals at the 2026 annual meeting

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
MTEX

Mannatech, Incorporated announced that all proposals submitted at its June 2, 2026 annual shareholders' meeting were passed. Shareholders elected two directors to the board, ratified BDO USA, P.C. as the independent auditor for 2026, and approved executive compensation on an advisory basis. The company also reported its 2025 financial results and highlighted its global health and wellness business operations.

Mannatech Announces Results of Annual Shareholders’ Meeting
MTEX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Shareholders elected two Class III directors to serve until 2029, ensuring board continuity and governance stability.
  • The appointment of BDO USA, P.C. as the independent registered public accounting firm for fiscal year 2026 was ratified, maintaining auditor consistency.
  • Advisory approval was given to the compensation of Mannatech's named executive officers, reflecting shareholder support of current executive pay practices.
  • Sectors impacted include health and wellness, nutritional supplements, and direct marketing/network marketing industries.

FLOWER MOUND, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (Nasdaq: MTEX) (the "Company"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at the Company’s annual shareholder meeting (the "Meeting") held Tuesday, June 2, 2026.

Mannatech’s Chairman of the Board, J. Stanley Fredrick, chaired the Meeting and Yasir Haider, Interim Chief Financial Officer, reported to the shareholders on the Company’s 2025 financial results.

At the close of business on April 6, 2026, the record date for determining shareholders entitled to vote at the Meeting, there were 1,929,670 shares of the Company’s common stock, par value $0.0001 per share, outstanding (the “Shares”). Proxies representing 1,369,880 Shares were received, validated, and voted at the Meeting, constituting 71.0% of the Shares entitle to vote.

The following matters were submitted and voted upon at the Meeting.

1. Mannatech shareholders voted on the election of two individuals to the Board of Directors as Class III Directors to hold office until 2029 as set forth below:

NameNumber of Shares
ForNumber of Shares
WithheldBroker
Non-VotesJohn A. Seifrick879,504213,248277,128Robert Toth937,930154,822277,128

2. Mannatech shareholders voted to ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ended December 31, 2026, as set forth below:

Number of Shares
ForNumber of Shares
AgainstNumber of Shares
AbstainingBroker
Non-Votes1,205,072164,4153930

3. Mannatech shareholders approved, on an advisory basis, the compensation of Mannatech’s named executive officers as set forth below:

Number of Shares
ForNumber of Shares
AgainstNumber of Shares
AbstainingBroker
Non-Votes947,313143,7401,699277,128

About Mannatech

Mannatech, Incorporated, is committed to transforming lives through the development, marketing, and sales of high-quality, proprietary nutritional supplements, topical and skin care and anti-aging products, and weight-management products distributed through its global network of independent associates and members. The company has been operating for more than 25 years of experience with operations in 25 markets^. For more information, visit Mannatech.com.

^Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

Please Note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “may,” “will,” “should,” "hope," “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “approximates,” “predicts,” “projects,” “potential,” and “continues” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

Investor Relations Contact Information:

Erin K. Barta
General Counsel and Corporate Secretary
972-471-7742
[email protected]

www.mannatech.com


Risks

  • Potential inability to attract and retain independent associates and members, which could impact sales and growth in the network marketing business model.
  • Regulatory changes and litigation risks inherent in the nutritional supplements and direct sales sectors.
  • Expansion into new international markets carries uncertainties and operational risks, particularly in evolving or complex regulatory environments.

More from Press Releases

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026 Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems Jun 5, 2026 Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study Jun 5, 2026